A former Director of the Neuropsychopharmacology Unit at Imperial College London, Professor Nutt performed the first MRI scan on a human brain that was under the influence of LSD, and previously advised the UK government on drug policy.
Nutt spoke on The Andy Rowe Show about the potential benefits of psychedelic medicines, including MDMA, LSD and psilocybin.
Read More
The UK-based provider of psychedelic-assisted therapy will acquire Axonklinikken AS to strengthen its European footprint.
Read More
Enveric shareholders now own approximately 68% of the combined company, which is listed on the Nasdaq.
Read MoreBeckley Psytech doses first patient with low-dose psilocybin in clinical trial.
Journey Clinica raises US$3m in funding.
FSD Pharma closes Lucid Psycheceuticals acquisition.
atai Life Sciences increases loan to IntelGenx by US$6m.
Nova Mentis applies to FDA for orphan drug designation.
Ketamine One signs LOI with Veteran Services USA for ketamine facility.
NeonMind appoints Dr Roumen Milev to advisory board.
Mind Cure joins Digital Therapeutics Alliance.
Mindset Pharma shares further preclinical safety and efficacy data.
Delic to acquire Ketamine Wellness Centers.
New head-to-head trial shows psilocybin is at least as effective as leading SSRI.
Measure filed in US to approve psychedelic research grants for PTSD.
Study finds ketamine infusions may be safe for adolescents with depression.
Psychedelics could aid in treating mental health disorders.
Why aren’t psychedelics addictive? An evidence-based review.
Mounting research suggests benefits of psychedelics as California considers legislation.
Ketamine monotherapy reduces suicidal ideation in adults with depression.
UK Home Office blamed for blocking rescheduling of psilocybin.
Californian psilocybin measure cleared to collect petition signatures.
Italian activists collect 500,000 signatures for a referendum on decriminalisation.